Article info

Download PDFPDF

Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Free

Authors

  • Thomas Dörner Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany Department of Medicine/Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin 10117, Germany; thomas.doerner{at}charite.de
View Full Text

Citation

Dörner T
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?

Publication history

  • Received August 27, 2020
  • Revised September 7, 2020
  • Accepted September 8, 2020
  • First published September 22, 2020.
Online issue publication 
October 12, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.